Abstract
Intensification of androgen deprivation therapy (ADT) with docetaxel or androgen receptor axis-targeted therapy (ARAT: abiraterone, apalutamide, enzalutamide) is the current standard of care for pts with mCSPC. However, biomarkers to guide treatment selection are lacking. We previously showed that dn-mCSPC pts with mtSPOP had improved survival outcomes with ADT (PMID: 32624276). Here, we hypothesized that mtSPOP would be associated with improved outcomes with ARAT + ADT but not with docetaxel + ADT.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
